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ABSTRACT
Objectives: The primary objective was to compare a
single, 6 ml, intra-articular injection of hylan G-F 20 with
placebo in patients with symptomatic knee osteoarthritis.
The safety of a repeat injection of hylan G-F 20 was also
assessed.
Methods: Patients with primary osteoarthritis knee pain
were randomly assigned to arthrocentesis plus a 6 ml
intra-articular injection of either hylan G-F 20 or placebo in
a prospective, double-blind (one injector/one blinded
observer) study. Results were evaluated at 4, 8, 12, 18
and 26 weeks post-injection. The primary outcome
criterion was change from baseline over 26 weeks in
Western Ontario and McMaster Universities (WOMAC)
Osteoarthritis Index A pain. Secondary outcome measures
included WOMAC A1 and C, patient global assessment
(PGA) and clinical observer global assessment (COGA)
and Outcome Measures in Rheumatology, Osteoarthritis
Research Society International responder rates. A 4-week,
open, repeat treatment phase evaluated safety only.
Results: A total of 253 patients (Kellgren–Lawrence
grade II or III) was randomly assigned. Patients receiving
hylan G-F 20 experienced statistically significantly greater
improvements in WOMAC A pain scores (20.15, SE
0.076, p=0.047), and several of the secondary outcome
measures (WOMAC A1, PGA and COGA), than patients
receiving placebo. There was no difference between the
safety results of the two groups. No increased risk of local
adverse events was observed in the open, repeat
treatment phase.
Conclusions: This placebo-controlled study demon-
strated that, in patients with knee osteoarthritis, a single
6 ml intra-articular injection of hylan G-F 20 is safe and
effective in providing statistically significant, clinically
relevant pain relief over 26 weeks, with a modest
difference versus placebo.
Trial registration number: NCT00131352.
Osteoarthritis is the most common joint disease
and one of the most frequent causes of physical
impairment.
1 Osteoarthritis of the knee has been
associated with a decrease in the elasticity and
viscosity of the synovial fluid,
2–4 which may alter
the transmission of mechanical forces to the
cartilage, possibly increasing its susceptibility to
mechanical damage, or wear and tear.
Viscosupplementation addresses the degradation
of hyaluronic acid (HA) in the synovial fluid of
patients with knee osteoarthritis by the addition of
exogenous HA, or its derivatives, by intra-articular
injection and is cited for the treatment of knee
osteoarthritis in the guidelines of several profes-
sional societies.
5–10
Hylan G-F 20 (Synvisc) is a high molecular
weight (average 6000 kDa) HA product consisting
of two cross-linked components. Approved in
several countries for the treatment of pain asso-
ciated with knee osteoarthritis, the recommended
treatment regimen for the treatment of knee
osteoarthritis pain is one 2 ml intra-articular
injection per week for three consecutive weeks.
11 12
In order to reduce the number of intra-articular
injections (and potential related side effects) a pilot
study was conducted, and the results suggested
that at 6 months post-injection, one 6 ml injection
performed at least as well as three 2 ml injections.
13
A single 6 ml injection may represent an attractive
alternative to the current treatment regimen,
reducing the number of intra-articular injections
required and thereby offering potential comfort
and safety benefits to patients.
The current study was designed to assess the
efficacy and safety of one 6 ml injection of hylan
G-F 20 in a 26-week, pivotal, prospective, multi-
centre, double-blind, randomised, placebo con-
trolled clinical trial.
METHODS
Ethics
The study was performed in accordance with the
principles of good clinical practice guidelines.
Ethics committee approvals and informed patient
consents were obtained. The study was registered
in the ClinicalTrials.gov National Institutes of
Health trial register under the identification
number NCT00131352.
Study design
At the screening visit patients gave their written,
informed consent and a physical examination was
performed on the knee to be treated (‘‘target
knee’’). A radiographic assessment was also per-
formed if no valid x ray had been taken within
3 months before screening was available.
Demographic data and medical history informa-
tion were collected.
Before commencing the study, a washout period
of prohibited pain and osteoarthritis medications
(analgesics and non-steroidal anti-inflammatory
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required.
Patients were randomly assigned to receive arthrocentesis
plus a 6 ml intra-articular injection of either hylan G-F 20 or
buffered physiological sodium chloride solution (PBS) (placebo)
on day 0.
Patients completed the Western Ontario and McMaster
Universities (WOMAC) Osteoarthritis Index Likert and patient
global assessment (PGA) questionnaires and a blinded evaluator
completed the clinical observer global assessment (COGA).
Safety assessments (including physical examination findings),
usage of concomitant medications and treatments and vital
signs were recorded until study completion. It was left to the
judgement of the clinical evaluator to decide whether each
target knee adverse event (AE) was related to the study
procedure (ie, expected with any intra-articular injection
procedure) or to the study material.
Patients were followed up 1, 4, 8, 12, 18 and 26 weeks after
injection.
To assess the safety of a repeat injection of 6 ml hylan G-F 20,
patientsfrombothgroupswerepermittedtoentera4-weekopen-
label repeat treatment phase 26 weeks after their initial injection
if they had no major safety concerns during the first course of
treatment and an average WOMAC A score of at least 1.
Patient selection
Patients were required to meet the American College of
Rheumatology criteria for osteoarthritis (knee pain for most
days of the previous month and osteophyte(s) at the joint
margin visible on x ray).
14
Figure 1 Study flow chart. AE, adverse event; ITT, intent-to-treat.
Table 1 Baseline characteristics for all randomly assigned patients (ITT population)
Hylan G-F 20
(N = 124)
Placebo
(N = 129)
Mean age, years (SD) 63.6 (9.64) 62.5 (9.17)
Mean BMI, kg/m
2 (SD) 29.08 (4.81) 29.77 (5.74)
Gender (M/F) 32/92 41/88
Tibiofemoral compartment with the most severe features of osteoarthritis,
N* (%)
Medial 93 (75.6) 103 (79.2)
Lateral 30 (24.4) 27 (20.8)
Modified Kellgren–Lawrence grade in most severe tibiofemoral compartment,
N* (%)
Grade II 63 (51.2) 51 (39.2)
Grade III 60 (48.8) 78 (60.0)
Grade IV 0 1 (0.8)
Previous corticosteroids in the target knee, N* (%) 40 (32) 31 (24)
Previous arthroscopy in the target knee, N* (%) 26 (21) 28 (22)
Total WOMAC score (0–4), mean (SD) 2.30 (0.44) 2.28 (0.39)
WOMAC A score (0–4), mean (SD) 2.30 (0.43) 2.25 (0.41)
Symptomatic osteoarthritis that was responsive to paracetamol and did not
require other therapy, N* (%)
In the contralateral knee 68 (55.3) 76 (58.5)
In either hip 12 (9.8) 18 (13.8)
Mean time since osteoarthritis diagnosis, months* (SD) (median, range) 77.38 (76.44)
(51.94, 3.1–350.9)
70.01 (64.43)
(47.34, 3.6–241.9)
*Safety population.
BMI, body mass index; ITT, intent-to-treat; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.
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of primary osteoarthritis of the target knee; radiographic
evidence of osteoarthritis in the medial and/or lateral tibiofe-
moral compartment (one or more osteophyte(s) and a measur-
able joint space on a standard radiograph taken within
3 months before screening); continued osteoarthritis pain in
the target knee despite conservative treatments. Patients were
required to have a score of 2 or 3 (0 to 4 scale) on question 1 of
the WOMAC (Likert version 3.1) pain (A) subscale (pain while
walking on a flat surface) as this is the most commonly reported
symptom in clinical practice and the protocol was designed to
weight this symptom more heavily. Included patients required a
mean score of 1.5–3.5 on the WOMAC A (total pain) subscore.
15
Main exclusion criteria were: secondary osteoarthritis in the
target knee; grade IV radiographic stage osteoarthritis (Kellgren–
Lawrence grading system);
16 clinically apparent tense effusion of
the target knee; significant valgus/varus deformities; viscosup-
plementation in any joint in the past 9 months; surgery in the
knee within the past 6 months; symptomatic osteoarthritis of
the contralateral knee or either hip unresponsive to paraceta-
mol; systemic or intra-articular injection of corticosteroids in
any joint within 3 months before screening.
Study treatments
Hylan G-F 20 (Synvisc-One, Genzyme Corporation, Ridgefield,
New Jersey, USA), was supplied in 6 ml PBS. Placebo was 6 ml
PBS. Both hylan G-F 20 and placebo were packaged identically
in order to maintain the study blind.
The injection approach was left to the unblinded injector’s
clinical discretion. Arthrocentesis was performed before inject-
ing hylan or PBS.
Concomitant medications and treatments
Paracetamol ((4000 mg/day) was permitted as rescue medica-
tion for the target knee. Other permitted medications were
analgesics/non-steroidal anti-inflammatory drugs with a half-
life of 5 h or less for indications other than osteoarthritis pain
(not to be taken for more than five consecutive days or
.10 days/month) and aspirin ((325 mg/day). However, for
48 h before a study visit, patients were required to abstain from
any paracetamol, pain or osteoarthritis medications.
Other permitted treatments may be reviewed in supplemen-
tary material 1 available online only.
Randomisation
Randomisation was performed by a centralised, interactive,
voice-response system and was done by site in computer-
generated blocks of four. Unblinded injectors were strictly
forbidden from discussing treatment allocation with patients
and clinical observers.
Power and sample size
The sample size estimation was based on the mean intergroup
difference in the WOMAC A pain subscale change from baseline
over 26 weeks. The following assumptions were made to
compute the sample size: anticipated overall treatment differ-
ence of 0.297; common SD of 0.725; dropout rate of 25%; two-
sided significance level of 5%. A resulting sample size of
approximately 250 patients (125 patients per group) provided
greater than 80% power to detect a difference between the
hylan G-F 20 and placebo groups over 26 weeks.
Efficacy analyses
The primary efficacy analysis was performed on the intent-to-
treat (ITT) population (all randomly assigned patients), based
on a repeated-measures analysis of covariance that was used to
test for intergroup differences in the WOMAC A (pain) subscore
over 26 weeks. The analysis of covariance model included terms
for treatment, site, time and time-by-treatment interaction, as
well as the baseline WOMAC A score as a covariate.
Secondary efficacy outcomes were analysed using generalised
estimating equations for a proportional odds logistic regression.
The generalised estimating equations model was fitted to the
observed data and included terms for baseline measure, site, visit,
treatment group and a visit-by-treatment group interaction.
These analyses included the difference between the groups from
baseline at week 26 in WOMAC A and the differences from
baseline over and at 26 weeks in WOMAC A1, WOMAC subscale
C, PGA, COGA, and the responders to treatment per the
Outcome Measures in Rheumatology, Osteoarthritis Research
Society International (OMERACT–OARSI) responder criteria.
17
For the WOMAC A1 responder analysis, patients were
classified at each post-baseline visit into a responder category
(yes/no). Those patients with at least a one-point category
improvement from baseline who did not withdraw due to lack
of efficacy were considered responders.
Safety analyses
The safety analyses were performed on the safety population
(all patients who received at least one injection of hylan G-F 20
or placebo).
RESULTS
Disposition of patients, baseline data
Patients were enrolled at 21 sites in the UK, France, the Czech
Republic, Germany, Belgium and The Netherlands. A total of
329 patients enrolled; 76 patients (23.1%) were screening
failures; 253 patients (73 men, 180 women) were randomly
assigned and analysed: 124 to receive hylan G-F 20 and 129 to
receive placebo. All 253 randomly assigned patients were
included in the safety population (hylan G-F 20 123 patients;
Figure 2 Mean change from baseline in the Western Ontario and
McMaster Universities (WOMAC) Osteoarthritis Index A (pain), intent-to-
treat population.
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the hylan G-F 20 group but received placebo in error and was
therefore counted in the placebo group for safety and the hylan
G-F 20 group for ITT efficacy.
A total of 232 patients (91.7%) completed the study. Nine
patients (7.3%) randomly assigned to hylan G-F 20 and 12
patients (9.2%) randomly assigned to placebo failed to complete
the study schedule as planned (fig 1).
There were no statistically significant, or clinically mean-
ingful, differences between treatment groups in any baseline or
demographic parameter (table 1).
Treatment efficacy
The treatment effect with hylan G-F 20 was statistically
significantly superior to placebo for the primary endpoint,
change in WOMAC A (pain) over 26 weeks (table 2 and
fig 2).
Hylan G-F 20 demonstrated an estimated change (absolute
change, adjusted for values, time and treatment) from baseline
over 26 weeks of 20.84, a mean percentage change in pain from
baseline of 36%. Patients in the placebo group had an estimated
change from baseline over 26 weeks of 20.69, a mean
percentage change in pain from baseline of 29%. The estimated
treatment difference between the two treatment groups over
the 26-week study was statistically significant (p=0.047).
Some, but not all, of the secondary endpoints, including
WOMAC A1 (walking pain), PGA and COGA, showed
statistically significant differences between the two groups
favouring hylan G-F 20 treatment (tables 3 and 4).
Seventy-one per cent (88/124) of the patients were WOMAC
A1 (walking pain) responders at week 18 in the hylan G-F 20
group compared with 53% (69/129) in the placebo group
(p=0.003). At week 26, 64% (79/124) of patients in the hylan
G-F 20 group were WOMAC A1 responders compared with 50%
(64/129) in the placebo group (p=0.028).
The change in WOMAC C (function) scores did not reach
statistical significance. Further exploratory analyses of predefined
covariates were carried out to understand better the lack of effect
of hylan G-F 20 on the WOMAC C endpoint. In patients without
any otherlower limbosteoarthritis (definedaship orcontralateral
knee involvement), those treated with Synvisc experienced a
greater change in WOMAC C than those treated with placebo
(20.71 and 20.55, respectively).
The OMERACT–-OARSI responder analysis over 26 weeks
approached statistical significance (p=0.059). At week 26, 73
patients (59%) in the hylan G-F 20 group and 66 patients (51%)
in the placebo group were responders.
Overall, patients consumed a mean daily dose of 0.26 g (SD
0.654 g) of paracetamol in the hylan G-F 20 group, and 0.28 g
(SD 0.570 g) in the placebo group. Throughout the study there
was no statistically significant difference in paracetamol
consumption between the two groups (p=0.370).
AE and safety
There were no target knee serious AE and no serious AE that
were related to the study treatment or the study procedure. The
overall frequency of AE was comparable between the two
treatment groups (hylan G-F 20, n = 70, 56.9%; placebo,
n = 79, 60.8%).
The most commonly reported AE were pain in the target knee
(coded as ‘‘arthralgia’’), joint stiffness, joint effusion and joint
swelling. The incidence of AE was slightly higher in the hylan
G-F 20 group (n = 7, 5.7%) than in the placebo group (n = 4,
3.1%) but this was not statistically significant (p=0.366)
(table 5). In addition, there were no statistically significant
differences between the groups in treatment-related (p=0.203)
Table 2 Primary efficacy endpoint—WOMAC A (pain) change over 26 weeks (ITT population)
Baseline
mean (SE)
26-Week
mean (SE)
Estimated
change (SE)
Estimated
difference
between
groups (SE) p Value
Hylan G-F 20 (n = 124) 2.30 (0.038) 1.43 (0.060) 20.84 (0.060) 20.15 (0.076) 0.047
Placebo (n = 129) 2.25 (0.036) 1.59 (0.058) 20.69 (0.058)
ITT, intent-to-treat; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.
Table 3 Secondary efficacy endpoints (ITT population): estimated between-group differences
Baseline
mean (SE)
Week 26
mean/overall
mean (SE)
Estimated
change (SE)
Estimated
between-group
difference p Value
WOMAC A (pain) change from
baseline at 26 weeks*
Hylan G-F 20 2.30 (0.04) 1.51 (0.074) 20.76 (0.07) 20.18 (0.097) 0.064
Placebo 2.25 (0.04) 1.69 (0.073) 20.58 (0.07)
WOMAC C (function) change from
baseline over 26 weeks{
Hylan G-F 20 2.29 (0.04) 1.62 (0.061) 20.66 (0.061) 20.03 (0.077) 0.679
Placebo 2.28 (0.04) 1.66 (0.059) 20.63 (0.059)
WOMAC C (function) change from
baseline at 26 weeks{
Hylan G-F 20 2.29 (0.04) 1.69 (0.076) 20.59 (0.076) 20.11 (0.100) 0.266
Placebo 2.28 (0.04) 1.80 (0.074) 20.48 (0.074)
*Week 26 mean in column 3; {overall mean in column 3. ITT, intent-to-treat; WOMAC, Western Ontario and McMaster Universities
Osteoarthritis Index.
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were of mild or moderate severity.
Repeat treatment phase
A total of 160 patients was treated in the open, repeat
treatment phase, of which 77 received a second injection of
hylan G-F 20 and 83 received a first injection of hylan G-F 20,
having received placebo during the initial treatment phase.
There were no target knee serious AE. In the group receiving a
second injection of hylan G-F 20 one patient (1.3%) experienced
target knee AE related to the study treatment and four patients
(5.2%) experienced target knee AE related to the study
procedure.
Patients who developed target knee AE during the initial
phase of the study, and who subsequently received repeat
treatment, did not experience target knee AE on repeat exposure
to hylan G-F 20. All treatment-related and procedure-related
target knee AE were of mild or moderate severity.
DISCUSSION
This study demonstrates that a single intra-articular injection of
hylan G-F 20 is safe and effective in providing statistically
Table 4 Secondary efficacy endpoints (ITT population): estimates of odds ratios
Week 26 subscore
Estimate of OR (placebo/hylan G-F 20)
(95% CI)
Hylan G-F 20
n (%)
Placebo
n (%) At week 26 Over 26 weeks
WOMAC A1 (walking pain) subscore
None 17 (13.7) 13 (10.1) 0.56 (0.35 to 0.92)
p=0.022
0.64 (0.45 to 0.91)
p=0.013
Mild 45 (36.3) 39 (30.2)
Moderate 41 (33.1) 42 (32.6)
Severe 11 (8.9) 19 (14.7)
Extreme 1 (0.8) 4 (3.1)
Patient global assessment
Very well 9 (7.3) 2 (1.6) 0.51 (0.31 to 0.82)
p=0.005
0.69 (0.50 to 0.96)
p=0.029
Well 33 (26.6) 27 (20.9)
Fair 50 (40.3) 54 (41.9)
Poor 21 (16.9) 31 (24.0)
Very poor 2 (1.6) 3 (2.3)
Clinician observer global assessment
Very well 13 (10.5) 8 (6.2) 0.56 (0.34 to 0.93)
p=0.025
0.71 (0.50 to 0.99)
p=0.041
Well 37 (29.8) 31 (24.0)
Fair 38 (30.6) 38 (29.5)
Poor 22 (17.7) 34 (26.4)
Very poor 5 (4.0) 6 (4.7)
OMERACT–OARSI responders
Responder 73 (58.9) 66 (51.2) 0.69 (0.41 to 1.16)
p=0.156
0.66 (0.44 to 1.02)
p=0.059
Non-responder 50 (40.3) 63 (48.8)
Based on OMERACT–OARSI responder criteria 43 (34.7) 52 (40.3)
Due to withdrawal before study completion 7 (5.6) 11 (8.5)
ITT, intent-to-treat; OMERACT–OARSI, Outcome Measures in Rheumatology, Osteoarthritis Research Society International; OR,
odds ratio; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.
Table 5 Target knee adverse events: safety population
Hylan G-F 20 Placebo
N = 123 N = 130
Preferred term n (% of patients) n (% of patients)
Any treatment-emergent target knee AE 44 (35.8) 44 (33.8)
Any treatment and/or procedure-related target knee AE 7 (5.7) 4 (3.1)
Arthralgia 2 (1.6) 3 (2.3)
Joint effusion 2 (1.6) 0 (0)
Arthritis 1* (0.8) 0 (0)
Arthropathy 1 (0.8) 0 (0)
Injection site pain 1 (0.8) 1 (0.8)
Any treatment-related target knee AE 4 (3.3) 1 (0.8)
Any procedure-related target knee AE 6 (4.9) 4 (3.1)
Related to treatment refers to unknown relationship to, or possibly, probably, or definitely related to treatment. Patients are counted
once for each unique adverse event (AE) and may have had more than one unique AE. If a patient had more than one occurrence of
the same AE, the strongest relationship to study treatment or injection procedure was included. Treatment groups reflect the actual
treatment received, not the randomised treatment. Patients may be counted in more than one category. *Patient withdrew from the
study due to target knee arthritis of moderate severity.
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WOMAC A1 (walking pain) over 26 weeks, with a modest
difference compared with placebo. Several secondary efficacy
results also show the superiority of hylan G-F 20 over placebo.
Pain while walking is particularly medically relevant for the
assessment of symptomatic relief and has been selected as the
primary efficacy measure in other studies of hylan G-F 20 or
other hyaluronans.
18–20 The OMERACT–OARSI responder
analysis also favoured hylan G-F 20 although statistical
significance was not reached (p=0.059).
This trial had a large placebo effect (20.69 change in mean
WOMAC A score over 26 weeks), which may explain why the
observed overall treatment difference (0.15) was weaker than
anticipated (0.297). The placebo effect in osteoarthritis treat-
ment has been re-evaluated in a recent meta-analysis showing
that it induces significant pain relief, especially in trials
involving intra-articular injections.
21 Furthermore, because the
actual therapeutic effect of arthrocentesis (with synovial fluid
aspiration if needed) has never been assessed, it is possible that
this contributed to the robust response in patients receiving
placebo. However, hylan G-F 20 was still significantly superior
to placebo in the primary and several of the secondary
endpoints.
Effect size is a way to measure effectiveness and to compare
clinical interventions.
22 The effect size of hylan G-F 20 versus
control in this study was 20.23 for WOMAC A at week 26. In
chronic pain conditions such as osteoarthritis, this modest effect
size should be interpreted as clinically relevant on an individual
patient basis as recommended by the IMMPACT consensus.
23 24
In addition, the accepted threshold for a minimum clinically
important improvement in osteoarthritis (12–18% improve-
ment in WOMAC A from baseline)
25 was exceeded in this study.
Patients treated with one 6 ml injection of hylan G-F 20
experienced a 31.3% improvement in WOMAC A from baseline
(p,0.001) at week 26.
The WOMAC C (function) subscale findings in the current
study are inconsistent with those from previous controlled
studies of hylan G-F 20.
18 26 However, our post-hoc analysis
showed that WOMAC C scores were improved in a subgroup of
patients without any other lower limb joint involvement,
suggesting that osteoarthritis occurring in other lower limbs
may contribute to substantial functional impairment, and may
confound the patient’s ability to detect improvement in the
target knee in a clinical trial setting.
Evaluation of the safety profile for the higher injected volume
(6 ml) of hylan G-F 20 was also a major objective of this study.
The similarity in the safety profiles of hylan G-F 20 and placebo
(PBS) is reassuring. No new, unrecognised AE were identified
during this study. The safety profile of hylan G-F 20 was
confirmed during the repeat treatment phase of the study,
indicating no increase in the risk of AE in the patients receiving
a second injection of hylan G-F 20. This finding contrasts with
previous reports of post-marketing studies, which suggest an
approximate threefold increased risk of local target knee AE
with a repeat course of hylan G-F 20.
19 The excellent safety
profile of the increased 6 ml dose translates to an improved
benefit-to-risk ratio for the patient.
CONCLUSIONS
This placebo-controlled study demonstrated that, in patients
with knee osteoarthritis, a single 6 ml intra-articular injection of
hylan G-F 20 is safe and effective in providing statistically
significant, clinically relevant pain relief over 26 weeks, with a
modest difference compared with placebo.
In daily practice the favourable benefit/risk profile of a single
injection of 6 ml hylan G-F 20 has the major advantage of
decreasing the number of injections from three to five to only
one.
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